A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies

BACKGROUND: Temsirolimus is an mTOR antagonist with proven anticancer efficacy. Preclinical data suggest greater anticancer effect when mTOR inhibitors are combined with cytotoxic chemotherapy. We performed a Phase I assessment of the combination of temsirolimus and capecitabine in patients with adv...

Descripción completa

Detalles Bibliográficos
Autores principales: Trivedi, Neel D., Armstrong, Samantha, Wang, Hongkun, Hartley, Marion, Deeken, John, Ruth He, A., Subramaniam, Deepa, Melville, Heather, Albanese, Chris, Marshall, John L., Hwang, Jimmy, Pishvaian, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957175/
https://www.ncbi.nlm.nih.gov/pubmed/33638305
http://dx.doi.org/10.1002/cam4.3672

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957175/
https://www.ncbi.nlm.nih.gov/pubmed/33638305
http://dx.doi.org/10.1002/cam4.3672

Ejemplares similares